Literature DB >> 9665973

Expression of the extracellular domain of the human immunodeficiency virus type 1 envelope protein and its fusion with beta-galactosidase in Saccharomyces cerevisiae.

W F Liu1, D Gao, Z N Wang.   

Abstract

Two envelope glycoprotein gene fragments were cloned from the proviral genome of the HXB2 isolate of human immunodeficiency virus (HIV). For the production of the two domains of the envelope gene product these cloned gene fragments were inserted into an Escherichia coli-yeast inducible shuttle vector fused to the galactokinase (GAL1) promoter. Cell extracts from strains of Saccharomyces cerevisiae harboring these two vectors (pYENV1 and pYENV2) were found to contain a specific protein with a size of 50 kDa when induced by galactose, while the protein could not be detected in extracts from control cells containing only the E. coli-yeast vector in the presence of galactose. Furthermore, another expression plasmid coding for fusion proteins from the majority of the external envelope glycoprotein (gp120) moiety and a large part of the beta-galactosidase was constructed. Antibodies from HIV type 1-positive sera could react with recombinant fusion polypeptides. Transformants could produce this fusion protein to a level of about 1.6% of the total protein content, as deduced from beta-galactosidase activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665973      PMCID: PMC95624          DOI: 10.1128/CDLI.5.4.592-594.1998

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  21 in total

Review 1.  Progress in vaccine development against SIV and HIV.

Authors:  D P Bolognesi
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

2.  Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects.

Authors:  A G Fisher; L Ratner; H Mitsuya; L M Marselle; M E Harper; S Broder; R C Gallo; F Wong-Staal
Journal:  Science       Date:  1986-08-08       Impact factor: 47.728

3.  Synergism between HIV gp120 and gp120-specific antibody in blocking human T cell activation.

Authors:  R S Mittler; M K Hoffmann
Journal:  Science       Date:  1989-09-22       Impact factor: 47.728

4.  Expression and characterization of a functional human immunodeficiency virus envelope glycoprotein in insect cells.

Authors:  D E Wells; R W Compans
Journal:  Virology       Date:  1990-06       Impact factor: 3.616

5.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.

Authors:  M Kowalski; J Potz; L Basiripour; T Dorfman; W C Goh; E Terwilliger; A Dayton; C Rosen; W Haseltine; J Sodroski
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

6.  Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule.

Authors:  J S McDougal; M S Kennedy; J M Sligh; S P Cort; A Mawle; J K Nicholson
Journal:  Science       Date:  1986-01-24       Impact factor: 47.728

7.  Synthesis and processing of human immunodeficiency virus type 1 envelope proteins encoded by a recombinant human adenovirus.

Authors:  R L Dewar; V Natarajan; M B Vasudevachari; N P Salzman
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

8.  Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160.

Authors:  P W Berman; L Riddle; G Nakamura; O K Haffar; W M Nunes; P Skehel; R Byrn; J Groopman; T Matthews; T Gregory
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

9.  Inhibitory influences of envelope glycoproteins of HIV-1 on normal immune responses.

Authors:  N Chirmule; V Kalyanaraman; N Oyaizu; S Pahwa
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1988

10.  Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus.

Authors:  J M McCune; L B Rabin; M B Feinberg; M Lieberman; J C Kosek; G R Reyes; I L Weissman
Journal:  Cell       Date:  1988-04-08       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.